Denali Therapeutics (DNLI) Treasury Shares (2018 - 2026)

Denali Therapeutics (DNLI) has 9 years of Treasury Shares data on file, last reported at $6.9 million in Q1 2026.

• On a quarterly basis, Treasury Shares rose 41.8% year-over-year to $6.9 million in Q1 2026; TTM through Mar 2026 was $6.9 million, a 41.8% increase from a year earlier, with the FY2025 full-year figure at $5.1 million, up 24.13% from the prior year.
• Treasury Shares for Q1 2026 stood at $6.9 million, up from $5.1 million in the prior quarter.
• Over the last five years, Treasury Shares for DNLI reached as high as $6.9 million in Q1 2026 and fell as low as $2.9 million in Q2 2022.
• Historically, Treasury Shares has averaged $4.2 million across 5 years, with a median of $4.0 million in 2024.
• Across the five-year window, Treasury Shares rose 7.43% in 2024 and jumped 41.8% in 2026, its largest moves.
• Year by year, Treasury Shares stood at $3.3 million in 2022, then gained by 9.14% to $3.6 million in 2023, then increased by 13.57% to $4.1 million in 2024, then increased by 24.13% to $5.1 million in 2025, then surged by 34.18% to $6.9 million in 2026.
• Per Business Quant data, the three most recent Treasury Shares figures were $6.9 million in Q1 2026, $5.1 million in Q4 2025, and $5.2 million in Q3 2025.